Acosta AG, Frías DMG, Reyes-Montes MR, Solís P, Acosta RMR

Language: Spanish
References: 32
Page: 107-111
PDF size: 127.16 Kb.

ABSTRACT

Within the oral cavity there are factors of resistance to oral infections, both specific and nonspecific, which help maintain the balance of the population of microorganisms that constitute the normal flora of the mouth. The most common oral diseases (gingivitis, periodontitis, candidiasis, recurrent ulcer disease) are associated with an imbalance of the population of commensal microorganisms in the mouth, and a poor host immune response, mainly caused by HIV infection. Conventional treatment of these diseases is based on the administration of corticosteroids and antibiotics, but often ineffective due to immunocompromised of the host, therefore the patients are treated additionally with immunostimulants. The immunomodulator more used are the leukocyte lysate (LL) and the synthetic thymic hormone (pidotimod). The use of these immunomodulators has great potential to stimulate the defense mechanisms, both prophylactic and therapeutic in various oral diseases. The characterization and synthesis of novel immunomodulators is an area of biomedical research of great interest to the general dentist.

REFERENCES

1. Sistig S, Cekic-Arambasin A, Rabatic S, Vucicevic-Boras V, Kleinheinz J, Piffko J. Natural immunity in recurrent aphthous ulceration. J Oral Pathol Med 2001; 30: 275-80.

2. Sistig S, Vucicevic-Boras V, Lukac J, Kusic Z. Salivary IgA and IgG subclasses in oral mucosal diseases. Oral Dis 2002; 8: 282-6.

3. Acosta-Altamirano G, Cruz A. Inmunología de las mucosas. México, D.F.: Distribuidora y Editorial Mexicana (DEMSA); 1992.

4. Sugawara S, Uehara A, Tamai R, Takada. Innate immune responses in oral mucosa. J Endotoxin Res 2002; 8: 465-8.

5. Leao JC, Ribeiro C, Carvalho A, Frezzini C, Porter S. Oral complications of HIV disease. Clinics 2009; 64: 459-70.

6. Frezzini C, Leao JC, Porter S. Current trends of HIV disease of the mouth. J Oral Pathol Med 2005; 34: 513-31.

7. Coogan MM, Greenspan J, Challacombe SJ. Oral lesions in infection with human immunodeficiency virus. Bull World Health Organ 2005; 83: 700-6.

8. Meurman JH, Uittamo J. Oral micro-organisms in the etiology of cancer. Acta Odontol Scandinavica 2008; 66: 321-6.

9. Bascones A, González Moles MA. Mecanismos inmunológicos de las enfermedades periodontales y periimplantarias. Av Periodon Implantol 2003; 15: 121-38.

10. Kornman K, Page RC, Tonetti MS. The host response to the microbial challenge in periodontitis: Assembling the players. Periodontology 2000; 14: 33-53.

11. Robinson PG. The significance and management of periodontal lesions in HIV infection. Oral Dis 2002; 8(Suppl. 2): 91-7.

12. Riena-Ras P, Ras-Monteón RM. Estomatitis aftosa: una consulta frecuente en atención primaria. Semergen 2000; 26: 186-91.

13. Porter S, Scully C. Aphthous ulcers (recurrent). Clin Evid 2005; 13: 1687-94.

14. Bascones-Martinez A, Figuero-Ruiz E, Esparza-Gomez GC. Oral ulcers. Med Clin 2005; 125: 590-7.

15. Castillo-Castillo A, Pérez-Borrego A, Guntiñas-Zamora MV. Uso del Inmunoferón en el tratamiento de la estomatitis aftosa recurrente en niños. Rev Cubana Estomatol 2006; 43(3).

16. Greenberg MS, Pinto A. Etiology and management of recurrent aphthous stomatitis. Curr Infect Dis Rep 2003; 5: 194-8.

17. Casiglia JM. Recurrent aphthous stomatitis: etiology, diagnosis, and treatment. Gen Dent 2002; 50: 157-66.

18. Berrón-Pérez R, Chávez-Sánchez R, Estrada-García I, et al. Indications, usage, and dosage of the transfer factor. Rev Alerg Mex 2007; 54: 134-9.

19. Richardson M, Rautemaa R. How the host fights against Candida infections. Front Biosci 2009; 14: 4363-75.

20. Akpan A, Morgan R. Oral candidosis. Postgrad Med J 2002; 78: 455-9.

21. Panizo M, Reviakina V. Candida albicans y su efecto patógeno sobre las mucosas. Rev Soc Ven Microbiol 2001; 21: 38-45.

22. Scully C, El-Kabir M. Candida and oral candidosis: A Review. Crit Rev Oral Biol Med 1994; 5: 125-57.

23. De la Peña H, Madrigal JA. Inmunoterapia celular contra el cáncer. Gamo 2006; 5: 61-4.

24. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Review of thymic hormones in cancer diagnosis and treatment. Int J Immunopharmacol 2000; 22: 261-73.

25. Alagona G, Ghio C, Villani V. Basis set, level, and continuum solvation effects on the stability of a synthetic dipeptide: PIDOTIMOD. J Phys Chem A 1999; 103: 5823-32.

26. Mantia IL, Grillo C, Mattina T, Zaccone P, Xiang M, Di Mauro M, Meroni PL, Nicoletti F. Prophylaxis with the novel immunomodulator pidotimod reduces the frequency and severity of upper respiratory tract infections in children with Down’s syndrome. J Chemother 1999; 11: 126-30.

27. Lawrence HS. Transfer factor. Adv Immunol 1969; 11: 195-266.

28. Kirkpatrick CH. Transfer factors: Identification of conserved sequences in transfer factors molecules. Mol Med 2000; 6: 332-41.

29. Bravo-Lindero AG. Actualidades en aféresis terapéutica. Rev Hemo Trombo 2007; 1: 25-9.

30. Acosta G, Ortiz J, Barragán L, Torres S, Santos JL. Linfocitos T CD4 y CD8 en calostro y sangre autóloga de mujeres mexicanas. Inmunología 1994; 13: 118-21.

31. Acosta-Altamirano G, Reyes-Montes MR, Hernández-Rodríguez M, Nava-Martínez LE, Pinacho FO. Inmunomoduladores y Afrodita. Rev Hosp Jua Mex 2006; 72: 22-7.

32. Correa-Meza BE, García-Estrada T, Vargas-Pérez A, Sánchez-Cordero V, Acosta-Ríos P, De León F, et al. En: 1er. Encuentro Internacional sobre Factor de Transferencia. Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional. 2006.